LightNews — News, ranked by scholars

www.youtube.com/watch?v=qNRx...

October 7, 2025 at 12:00 AM

𓂀 US Stock Pros ☥

@usstockpros.bsky.social

“Positive news on $QNRX and $SES today, creating potential opportunities for quick gains. Watch the moves and seize the moment.

#Trading #StockMarket #Opportunities”

January 23, 2025 at 1:07 PM

Woke Sky Reflections

@wokeskyreflections.bsky.social

youtube.com/watch?v=qNRx...

February 8, 2025 at 2:14 AM

deehopeful.bsky.social

@deehopeful.bsky.social

youtube.com

February 9, 2025 at 2:55 PM

Ms o

@sciencyish.bsky.social

youtube.com/watch?v=qNRx...
Hope! Play entire podcast!

youtube.com

February 8, 2025 at 4:49 AM

Ribbon the Educated Skunk 🦨

@ribbonchannel.bsky.social

fans of ojamajo doremi's first ED might find the beginning of this Rachmaninov piece a little familiar... www.youtube.com/watch?v=QNRx...

Rachmaninov - Symphony No. 2 Op. 27 III. Adagio: Adagio (LSO)

YouTube video by whiteocean78

youtube.com/watch?v=qNRx...

August 18, 2026 at 12:19 AM

Not a TRUMP supporter

@flash1177.bsky.social

youtube.com

February 8, 2025 at 1:25 AM

Kris a.k.a. Evil Genius 💙 ᓚᘏᗢ 📖 (֊⎚-⎚) 💙

@kshipman70.bsky.social

PISSED OFF Judges GET REVENGE on Trump FINALLY
www.youtube.com/watch?v=qNRx...

February 8, 2025 at 4:24 AM

ChimPanion

@chimpanion.bsky.social

www.youtube.com/watch?v=qNRx... #MeidasMighty #BlueCrew #RainbowWarriors #Scouts Need to see this report by Popok on legal news.👇

February 8, 2025 at 2:52 AM

Biostock

@biostock.bsky.social

🟢 #$QNRX — FDA Designation
FDA Conditional Brand Name Approval - QYLEKI
The FDA conditionally approved QYLEKI as the proposed brand name for QRX003 (sirolimus lotion 4%) for Netherton Syndrome, a labeling milestone signaling progress toward NDA filing. Final ap…

https://biostock.app/symbols/QNRX

June 23, 2026 at 8:22 PM

LGBTQIA+ News USA Weather and things of interest

@katrina26.bsky.social

Rule of law is winning :)
www.youtube.com/watch?v=qNRx...

Rachmaninov - Symphony No. 2 Op. 27 III. Adagio: Adagio (LSO)

February 8, 2025 at 1:12 AM

guydauncey.bsky.social

@guydauncey.bsky.social

In case anyone has not heard this stunning piece of music.... www.youtube.com/watch?v=QNRx...

YouTube video by whiteocean78

Quoin Pharmaceuticals Secures FDA Clearance for Groundbreaking Netherton Syndrome Treatment Study

January 23, 2025 at 1:04 AM

Stocknear

@stocknear.bsky.social

$QNRX Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a second whole-body QRX003 netherton syndrome clinical study.

May 22, 2025 at 12:39 PM

StockTitan

@stocktitan.net

#QNRX Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-to-initiate-new-qrx003-yxz46qdiinvd.html

FDA greenlights Quoin's pivotal clinical trial for QRX003, a potential first-ever treatment for Netherton Syndrome. Study aims to demonstrate real-world efficacy.

Quoin's Netherton Syndrome Treatment Shows Dramatic Clinical Improvement in Early Trial Data

December 19, 2024 at 1:00 PM

StockTitan

@stocktitan.net

#QNRX Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-announces-positive-interim-data-from-two-z73jdrxydf85.html

Quoin Pharma's QRX003 demonstrates significant symptom reduction in Netherton Syndrome patients, with rapid improvements in severity scores and no safety concerns.

Biotech catalyst calendars and drug pipelines • BioPharmCatalyst

December 18, 2024 at 1:18 PM

BioPharmCatalyst

@biopharmcatalyst.bsky.social

$VIGL reported Phase 1 data for VG-3927, a once-daily oral TREM2 agonist for Alzheimer’s, showing favorable safety, high brain penetrance, and up to ~50% dose-dependent sTREM2 reduction in CSF.

See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/vi...

$XCUR $CDT $SLS $ALXO $IVA $QNRX

Profit on the stock market by investing in biotech stocks

www.biopharmcatalyst.com

January 23, 2025 at 9:11 PM

BioPharmCatalyst

@biopharmcatalyst.bsky.social

$XCUR acquired GPCR Therapeutics USA and entered a License & Collaboration Agreement, with Exicure agreeing to milestone and royalty payments

See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2025/ex...

$CDT $IVA $VIGL $QNRX $BIIB

January 23, 2025 at 1:28 PM

PRISM MarketView

@prismmarketview.bsky.social

PRISM MarketView M☀️rning M☀️vers:
Top Gainers
#PMAX up + 117%
#QNRX up +151%
#GWM up +141%
#ELBM up +65%
Top Decliners
#TVRD down -87.7%
#BYND down -54.9%

October 13, 2025 at 1:00 PM

Sean Dekmar

@dekmartrades.bsky.social

News Scanner (LINK: foxrunner.com?fpr=newsscan...)

#stockmarketnews #daytrading #foxrunner #livenews
$CTNT $PSQH $CTOR $GWAV $JYD $SOAR $UAMY $KDLY $ATIP $SER $AMST $QNRX $RENB $TELO $AMBO $HTL $IDAI $AMD $TSLA $NVDA $AAPL $AMZN $IONQ $AMD $PLTR $DTJ $PSQH $PLTR $CTNT $ZJK $SNTI

December 3, 2024 at 7:55 PM

StockTitan

@stocktitan.net

#QNRX Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-announces-fda-clearance-to-initiate-second-ssoc9tma8h25.html

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to

May 22, 2025 at 11:30 AM

Harpy

@yourharpyeagle.bsky.social

DC Federal judges are getting revenge against Trump. Backed by angry attorneys and people alike.

Ignore the chaos machine, it won't get far unless we are scared of it. Stay focused.
www.youtube.com/watch?v=qNRx...

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

February 8, 2025 at 3:38 AM

StockTitan

@stocktitan.net

#QNRX Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-announces-additional-positive-interim-data-pbhdcmrpxs8z.html

Quoin Pharmaceuticals announces additional positive interim data from its ongoing open-label Netherton Syndrome clinical study. The study involves QRX003, a treatment administered twice daily. After 12 weeks, the first subject showed significant improvements across all measured clinical endpoints:M-IASI: Reduced from 18 to 3 (lower scores indicate improvement)WINRS: Decreased from 7 to 2 (measures itch severity on an 11-point scale)IGA: Improved from 'Moderate' to 'Almost Clear'Photographs demonstrating the subject's skin improvements are available on Quoin's website. No safety concerns were identified during the study. Patient satisfaction scores were highly positive and improved further after 12 weeks. Quoin CEO, Dr. Michael Myers, expressed excitement over the results, highlighting the potential efficacy of QRX003 and the absence of safety issues. The company is preparing for a 'whole body' clinical study at Northwestern University, with FDA clearance already obtained. Data from this study will support a New Drug Application for QRX003 as the first approved treatment for Netherton Syndrome. Quoin anticipates providing more updates throughout 2025.